UCLA Department of Urology
Welcome,         Profile    Billing    Logout  
 7 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chamie, Karim
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
NCT05775471: Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Recruiting
2
21
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG-22CE, Enfortumab Vedotin-ejfv, Padcev, MR Urography, Magnetic Resonance Urography, Nephroureterectomy, Ureteronephrectomy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC, Seagen Inc.
Renal Pelvis and Ureter Urothelial Carcinoma
12/27
12/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting
1
60
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
12/24
03/25
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Salmasi, Amirali H
UTOPIA, NCT06331299: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Recruiting
3
87
US
UGN-103, UGN-103 (mitomycin) for intravesical solution
UroGen Pharma Ltd.
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
03/25
03/26
Sachdeva, Ankush
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
NCT05775471: Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Recruiting
2
21
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG-22CE, Enfortumab Vedotin-ejfv, Padcev, MR Urography, Magnetic Resonance Urography, Nephroureterectomy, Ureteronephrectomy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Jonsson Comprehensive Cancer Center, Merck Sharp & Dohme LLC, Seagen Inc.
Renal Pelvis and Ureter Urothelial Carcinoma
12/27
12/28
CaRe, NCT06056791: Study of INKmune in Patients With mCRPC ( Prostate)

Recruiting
1/2
30
US
INKmune
Inmune Bio, Inc.
Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
05/25
11/25
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
NCT04857502: 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Recruiting
1
30
US
99mTc-based PSMA Imaging and Surgery Agent, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon
Jonsson Comprehensive Cancer Center
Prostate Carcinoma, Recurrent Prostate Carcinoma
06/25
06/26
NCT05398302: Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Recruiting
1
30
US
Image Guided Biopsy, Image-Guided Biopsy, Imaging Guided Biopsy
Jonsson Comprehensive Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
12/25
12/26
NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Available
N/A
US
89Zr-DFO-girentuximab
Telix Pharmaceuticals (Innovations) Pty Limited
Clear Cell Renal Cell Carcinoma
 
 
NCT06047509: Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance

Active, not recruiting
N/A
2
US
Focal Laser Ablation, FLA
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Prostate Cancer
10/25
10/26
#HOPE4KIDNEY, NCT05820087: The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy

Recruiting
N/A
68
US
HistoSonics Edison System, Histotripsy
HistoSonics, Inc.
Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
07/25
05/30
NCT03193541: A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

Recruiting
N/A
900
Japan, US
Cedars-Sinai Medical Center, Nonagen Bioscience Corporation, Nara Medical University, University of California, Los Angeles, University of Rochester, National Cancer Institute (NCI), University of Texas, Southwestern Medical Center at Dallas, VA Long Beach Healthcare System, Nara Prefecture Seiwa Medical Center
Bladder Cancer
12/25
12/25
Leanez, Luis
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting
1
60
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25

Download Options